GSA Capital Partners LLP Reduces Stake in Phibro Animal Health Corporation $PAHC

GSA Capital Partners LLP lessened its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 78.3% during the 3rd quarter, Holdings Channel.com reports. The fund owned 9,243 shares of the company’s stock after selling 33,423 shares during the period. GSA Capital Partners LLP’s holdings in Phibro Animal Health were worth $374,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PAHC. EverSource Wealth Advisors LLC increased its stake in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after purchasing an additional 2,685 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Phibro Animal Health by 768.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after buying an additional 4,079 shares in the last quarter. Cornerstone Investment Partners LLC purchased a new position in shares of Phibro Animal Health in the 3rd quarter valued at $209,000. Balboa Wealth Partners acquired a new stake in Phibro Animal Health during the 3rd quarter worth $216,000. Finally, Arizona State Retirement System purchased a new stake in Phibro Animal Health in the third quarter valued at $243,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Stock Up 3.0%

PAHC opened at $54.70 on Friday. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $56.30. The business has a 50 day moving average price of $43.41 and a two-hundred day moving average price of $40.66. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The company has a market cap of $2.22 billion, a PE ratio of 24.31, a P/E/G ratio of 0.82 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The business had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a yield of 0.9%. Phibro Animal Health’s dividend payout ratio is presently 21.33%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PAHC. JPMorgan Chase & Co. raised their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Finally, Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Phibro Animal Health currently has an average rating of “Hold” and a consensus price target of $37.50.

Insider Buying and Selling

In other news, CEO Jack Bendheim sold 110,842 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $48.38, for a total value of $5,362,535.96. Following the completion of the sale, the chief executive officer owned 122,958 shares in the company, valued at approximately $5,948,708.04. This trade represents a 47.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 302,720 shares of company stock worth $14,393,233. 50.13% of the stock is currently owned by corporate insiders.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.